




Argos Therapeutics  
Investor Relations Department  
4233 Technology Drive  
Durham, NC 27704  
United States

[Visit IR website](#)   
[Sign-up for Email alerts](#) 

**NASDAQ: ARGS**


Last Trade:	0.16
Trade Time:	3:59 PM ET Jan 17, 2018
Change:	0.02  (+15.297%)
Day Range	0.14 - 0.17
52-Week Range	0.13 - 5.30
Volume	6,407,358

Stock information is provided by eSignal,  
stock charts provided by EDGAR Online.  
Stock data is delayed approximately 20  
minutes.

## Company Profile

Argos Therapeutics is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases based on its Arcelis™ technology platform. Using biological components from each patient, Arcelis-based immunotherapies employ the patient's dendritic cells to activate an immune response specific to the patient's disease. Argos' most advanced product candidates include AGS-003 for the treatment of metastatic renal cell carcinoma, or mRCC, and AGS-004 for the treatment of HIV. [\(more\)](#)

## Stock Performance



## Press Releases [\[ View all \]](#)

- Jan 8, 2018*  
[Argos Announces \\$1.5 Million Equity Investment by Lummy \(Hong Kong\), Ltd.](#)
- Nov 28, 2017*  
[Argos Provides Financial Update](#)
- Nov 11, 2017*  
[Argos Therapeutics Provides Update on Immunology Data from the Phase 3 ADAPT Trial Presented at the SITC 2017 Annual Meeting](#)
- Nov 9, 2017*  
[Argos Reports Third Quarter 2017 Financial Results and Operational Highlights](#)
- Nov 6, 2017*  
[Argos Announces Receipt of Milestone Payment from Lummy \(Hong Kong\) Co. Ltd.](#)

## Financials [\[ View all \]](#)

- Mar 16, 2017*  
[Annual Report \(10-K\)](#)
- Jul 6, 2017*  
[Proxy Statement \(DEF 14A\)](#)
- Nov 9, 2017*  
[Quarterly Report \(10-Q\)](#)
- Aug 9, 2017*  
[Quarterly Report \(10-Q\)](#)
- May 10, 2017*  
[Quarterly Report \(10-Q\)](#)